Our Vision is to be the world’s leading and most valued generics and biosimilars company.
Download full reportIn our second year as a standalone global leader, the Sandoz strategy remains fundamentally unchanged. We are building consistently on our solid foundations, with our strong leadership in home market Europe and strategic leadership ambitions in the key US market, to succeed in the long term. The strategy is evolving in three clear phases:
Leveraging our freedom as a
standalone company
Establishing a world-class generics and
biosimilars company
Long-term leadership
Sandoz continues to optimize its product mix, with mid-term growth driven by a combination of increased volume in the base business and launches across generics and biosimilars. Together with the benefit from strong existing infrastructure and customer relationships, this generates attractive cash flow to support future investments.
Europe | 0m | 0% | |
North America | 0m | 0% | |
International | 0m | 0% |
Europe | USD 0.0bn | 0% | |
North America | USD 0.0bn | 0% | |
International | USD 0.0bn | 0% |
Driving impact and access to healthcare is at the core of what we do. Championing sustainability, empowering our people, and governing with integrity help us to advance our Purpose and integrate it into our strategy.
Pioneering access to generic and biosimilar medicines worldwide is central to what we do. We produce quality medicines at scale, making them more accessible and affordable, while partnering to accelerate the pace of change.
We prioritize environmental sustainability, driving down our carbon footprint and preserving natural resources.
People are central to our Purpose of pioneering access for patients. We foster a safe and diverse workforce and develop exceptional talent and an inclusive pioneering culture.
We promote strong corporate governance that drives sound risk management, ethical behavior, and safe high-quality products.